EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Precision Neoantigen Discovery Using Large-Scale Immunopeptidomes and Composite Modeling of MHC Peptide Presentation

Rachel Marty Pyke, Datta Mellacheruvu, Steven Dea, Charles Abbott, Simo V Zhang, Nick A Phillips, Jason Harris, Gabor Bartha, Sejal Desai, Rena McClory, John West, Michael P Snyder und 2 weitere

Molecular & Cellular Proteomics · 2023-04 · 22 (4) · 100506

DOI: 10.1016/j.mcpro.2023.100506 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular & Cellular Proteomics, 2023-04. Verfasst von Rachel Marty Pyke und 13 weiteren Autor:innen. Beteiligte Einrichtung: Personalis, Inc, Menlo Park, California, USA. Hauptthemen laut MEDLINE: Peptides, Neoplasms. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Major histocompatibility complex (MHC)-bound peptides that originate from tumor-specific genetic alterations, known as neoantigens, are an important class of anticancer therapeutic targets. Accurately predicting peptide presentation by MHC complexes is a key aspect of discovering therapeutically relevant neoantigens. Technological improvements in mass spectrometry-based immunopeptidomics and advanced modeling techniques have vastly improved MHC presentation prediction over the past 2 decades. However, improvement in the accuracy of prediction algorithms is needed for clinical applications like the development of personalized cancer vaccines, the discovery of biomarkers for response to immunotherapies, and the quantification of autoimmune risk in gene therapies. Toward this end, we generated allele-specific immunopeptidomics data using 25 monoallelic cell lines and created Systematic Human Leukocyte Antigen (HLA) Epitope Ranking Pan Algorithm (SHERPA), a pan-allelic MHC-peptide algorithm for predicting MHC-peptide binding and presentation. In contrast to previously published large-scale monoallelic data, we used an HLA-null K562 parental cell line and a stable transfection of HLA allele to better emulate native presentation. Our dataset includes five previously unprofiled alleles that expand MHC diversity in the training data and extend allelic coverage in underprofiled populations. To improve generalizability, SHERPA systematically integrates 128 monoallelic and 384 multiallelic samples with publicly available immunoproteomics data and binding assay data. Using this dataset, we developed two features that empirically estimate the propensities of genes and specific regions within gene bodies to engender immunopeptides to represent antigen processing. Using a composite model constructed with gradient boosting decision trees, multiallelic deconvolution, and 2.15 million peptides encompassing 167 alleles, we achieved a 1.44-fold improvement of positive predictive value compared with existing tools when evaluated on independent monoallelic datasets and a 1.17-fold improvement when evaluating on tumor samples. With a high degree of accuracy, SHERPA has the potential to enable precision neoantigen discovery for future clinical applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PeptidesNeoplasmsHumansHistocompatibility Antigens Class IHistocompatibility Antigens Class IIMajor Histocompatibility ComplexHLA Antigens

Stichwörter der Autor:innen

MHCcancercancer vaccinesimmunologyimmunopeptidomicsmachine learningmajor histocompatibility complexneoantigen predictionneoantigensnext-generation sequencing

Substanzen

PeptidesHistocompatibility Antigens Class IHistocompatibility Antigens Class IIHLA Antigens

Autor:innen und Institutionen

  • Personalis, Inc, Menlo Park, California, USA.
  • Department of Genetics, Stanford University, Palo Alto, California, USA.
  • Personalis, Inc, Menlo Park, California, USA. Electronic address: sean.boyle@personalis.com.

Zitieren

APA

Pyke, R. M., Mellacheruvu, D., Dea, S., Abbott, C., Zhang, S. V., Phillips, N. A., Harris, J., Bartha, G., Desai, S., McClory, R., West, J., Snyder, M. P., Chen, R., & Boyle, S. M. (2023). Precision Neoantigen Discovery Using Large-Scale Immunopeptidomes and Composite Modeling of MHC Peptide Presentation. Molecular & Cellular Proteomics, 22(4), 100506. https://doi.org/10.1016/j.mcpro.2023.100506

Vancouver

Pyke RM, Mellacheruvu D, Dea S, Abbott C, Zhang SV, Phillips NA, et al. Precision Neoantigen Discovery Using Large-Scale Immunopeptidomes and Composite Modeling of MHC Peptide Presentation. Molecular & Cellular Proteomics. 2023;22(4):100506. doi:10.1016/j.mcpro.2023.100506

BibTeX
@article{Pyke2023,
  author = {Pyke, Rachel Marty and Mellacheruvu, Datta and Dea, Steven and Abbott, Charles and Zhang, Simo V and Phillips, Nick A and Harris, Jason and Bartha, Gabor and Desai, Sejal and McClory, Rena and West, John and Snyder, Michael P and Chen, Richard and Boyle, Sean Michael},
  title = {Precision Neoantigen Discovery Using Large-Scale Immunopeptidomes and Composite Modeling of MHC Peptide Presentation},
  journal = {Molecular & Cellular Proteomics},
  year = {2023},
  volume = {22},
  number = {4},
  pages = {100506},
  doi = {10.1016/j.mcpro.2023.100506}
}
Kostenlos starten →